Indication
KRAS G12S
1 clinical trial
1 product
Clinical trial
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-01
Product
ELI-002